WEBINAR

Photobiomodulation Coding, Billing, and Reimbursement

Kevin J. Corcoran, COE, FNAO

Principal and Co-owner
Corcoran & Corcoran

The Valeda^® Light Delivery System has received FDA authorization for the treatment of dry age-related macular degeneration (AMD). This webinar will provide:

Current reimbursement considerations related to photobiomodulation therapy
Coding, coverage, and billing practices
Practical guidance on navigating reimbursement pathways for this emerging treatment option

Registration

First Name*

Error: Please enter your first name.

Last Name*

Error: Please enter your last name.

Your Email*

Error: Please enter your email.

State*

This field is required.

Practice Name

This field is required.

Phone number

This field is required.

Marketing Permission

Yes, I consent to the privacy policy.*

Valeda Indications for Use
The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:

The presence of at least 3 medium drusen (> 63 μm and ≤ 125 μm in diameter), or large drusen (> 125 μm in diameter), or non-central geographic atrophy, AND
The absence of neovascular maculopathy or center-involving geographic atrophy.

After about two years, the Valeda Light Delivery System treatment provides improved mean visual acuity of approximately one line of visual acuity (ETDRS) compared to those not receiving the treatment.

Contraindications
As a precaution, patients have not been tested and should not be treated with Valeda if they have any known photosensitivity to yellow light, red light or near-infrared radiation (NIR), or if they have a history of light-activated central nervous system disorders (e.g. epilepsy, migraine). In addition, patients should not receive treatment within 30 days of using photosensitizing agents (e.g. topicals, injectables) that are affected by 590, 660, and/or 850 nm light before consulting with their physician.

Refer to the Valeda Light Delivery System User Manual for full Important Safety Information.

Legal:
Program sponsored by LumiThera, Inc. Except as permitted under the United States Copyright Act of 1976, no part of this program may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of Corcoran & Corcoran. CPT and all CPT codes are copyrighted by the American Medical Association with all the rights and privileges pertaining.